



NEWS RELEASE

Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST

2/3/2015

TEL AVIV, Israel--(**BUSINESS WIRE**)--Compugen Ltd. (**NASDAQ: CGEN**) today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 10, 2015 to review fourth quarter and year-end 2014 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and year-end results will be released on the Company's website (www.cgen.com), prior to the call.

To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugen's website, located at the following [link](#).

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5904 internationally. The replay will be available through February 12, 2015.

About Compugen

Compugen is a leading drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. The discovery and development of monoclonal antibody therapeutic candidates against selected Compugen-discovered

novel target candidates is performed by Compugen's wholly-owned U.S. subsidiary located in South San Francisco. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. For additional information, please visit Compugen's corporate website at **www.cgen.com**.

CONTACTS

Compugen Ltd.

Tsipi Haitovsky, +972-52-598-9892

Global Media Liaison

tsipih@cgen.com